Kura Oncology's (KURA) Zifto a Therapeutic Partner to FLT-3 Inhibitors - Citizens
Tweet Send to a Friend
Citizens analyst Reni J. Benjamin reiterated a Market Outperform rating and $24.00 price target on Kura Oncology (NASDAQ: KURA).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
